Updates stock activity

** Enliven Therapeutics' ELVN.O shares reverse premarket losses and soar on Fri after upsized $400 mln follow-on priced

** ELVN stock up 12.1% at $45.23 after hitting a six-week high

** Biopharma firm late Thurs sold ~8.9 mln shares and pre-funded warrants to buy ~1.7 mln shares at $37.50

** Offering size increased from $250 mln

** Stock finished up ~9% at $40.36 on Thurs after co's leukemia drug, ELVN-001, showed encouraging early-stage results

** Co intends to use net proceeds from offering to advance ELVN-001 in ongoing and planned clinical trials, among other purposes, per the prospectus

** Jefferies, Goldman Sachs, Morgan Stanley and Barclays joint bookrunners, along with Mizuho

** Burlingame, California-based Enliven has 60.9 mln shares outstanding

** With the move, stock has nearly tripled YTD

** All 12 analysts rate the stock "strong buy" or "buy"; median PT $59.50, according to LSEG data